Induction of allogeneic tumour‐ and lymphokine‐activated lymphocytes against hepatocellular carcinoma
- 1 April 1992
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 7 (2) , 136-141
- https://doi.org/10.1111/j.1440-1746.1992.tb00950.x
Abstract
For clinical application of adoptive immunotherapy against hepatocellular carcinoma (HCC), it is not easy to prepare tumour specific effector cells such as cytotoxic T lymphocytes (CTL). To induce potent and broad‐spectrum effectors, allogeneic cultured hepatoma cell lines (JHH‐4 and HuH‐6) were used as stimulators of peripheral blood lymphocytes (PBL) instead of autologous HCC cells. Allogeneic tumour‐ and lymphokine‐activated killer cells (ATLAK) were generated by a mixed culture of lymphocytes and allogeneic cultured tumour cells with recombinant interleukin‐2 (rIL‐2). The tumour‐killing activity of ATLAK induced by HuH‐6 was confirmed against HuH‐6 and other different HCC cell lines (JHH‐2, HuH‐7 and PLC). These activated lymphocytes were significantly more potent than lymphokine‐activated killer cells (LAK) in [51Cr]‐releasing assay. The JHH‐4 stimulated ATLAK was reactive not only with JHH‐4 but also with JHH‐2. The lysis of allogeneic targets could be partially inhibited by anti‐CD8 and anti‐CD3 but not by anti‐CD4. Anti‐tumour cytotoxicity in these cultures might be mediated by CD3+CD56‐ and CD3+CD56+ effectors. These results imply that adoptive immunotherapy for HCC with ATLAK may be more feasible than that with LAK.Keywords
This publication has 15 references indexed in Scilit:
- Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.Proceedings of the National Academy of Sciences, 1989
- Combined effects of interferon α and interleukin 2 on the induction of a vascular leak syndrome in miceCancer Immunology, Immunotherapy, 1989
- Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and interleukin-2Cancer Chemotherapy and Pharmacology, 1989
- Functional and phenotypic analysis of tumor-infiltrating. Lymphocytes isolated from human primary and metastatic. Liver tumors and cultured in recombinant interleukin-2Cancer, 1989
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Clinical effects and toxicity of interleukin-2 in patients with cancerCancer, 1986
- Direct evidence for the existence of nominal antigen binding sites on T cell surface Ti α-β heterodimers of MHC-restricted T cell clonesCell, 1986
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen).The Journal of Experimental Medicine, 1985
- Tactics of Acclimation: Morphological Changes of Sponges in an Unpredictable EnvironmentScience, 1984